TrialLancet (London, England)2023

Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial.

Robert J Motzer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.